TCR-T Therapy Yields Some Responses in HBV-Related Hepatocellular Carcinoma
The median progression-free survival was 11 months and the SCG101 was well-tolerated.
Lynch Syndrome Neoantigen Vaccine is Well-Tolerated, Demonstrates Immunogenicity
Microsatellite instability (MSI) tumors are frequently found in people with Lynch syndrome, one of the most common hereditary colorectal cancers.
CRISPR CAR Therapy Shows 100% ORR in NHL in Chinese Trial
BRL Medicine is also enrolling a phase 1/2 multicenter trial evaluating BRL-201 at lower dose ranges.
A2 Bio’s Screening Study Identifies Eligible Patients for Treatment With Tmod CAR-T
The BASECAMP-1 screening study has now identified 28 patients whose solid tumors are positive for HLA-A*02 LOH.
T-Cell Engagers Show Potential in HPV16+ and WT1+ Cancers
Patients with HNSCC had a median overall survival (OS) of 20.8 months and a 12-month OS rate of 59%.
mRNA/LNP CAR-M Shows Promise for Treating Solid Tumors in Preclinical Research
In terms of safety, it was noted that repeated administration of CAR mRNA/LNP was well-tolerated by mice.
Diane Simeone, MD, on Screening Patients for CAR-T Eligibility Before Solid Tumor Relapse
Simeone discussed the progress and challenges seen so far in the BASECAMP-1 observational study.
Diane Simeone, MD, on Addressing Unmet Needs in Colorectal Cancer, NSCLC, and Pancreatic Cancer
Simeone discussed the design of BASECAMP-1, an observational study for patients previously treated for solid tumors who are at a high risk of relapse.
Amod Sarnaik, MD, on New Frontiers in Cell Therapy for Advanced Melanoma
Sarnaik discussed several potential areas of innovation on the horizon.
Terese Hammond, MD, on Investigating iNKT Cells in COVID-Associated ARDS
The director of the CCU/ICU at Saint John’s Health Center discussed unmet respiratory treatment needs in the beginning of the COVID-19 pandemic.
Amod Sarnaik, MD, on Lifileucel’s Place in the Treatment Lanscape for Advanced Melanoma
Sarnaik discussed the investigational TIL therapy’s potential as an additional option for patients.
Combination Adenovirus Therapy Shows Survival Gains in Newly Diagnosed High-Grade Glioma
CAN-2409 transduces tumor cells with the thymidine kinase gene, sensitizes these cells to valacyclovir, and stimulates patients’ immune response.
CT-0508 Demonstrates Cytotoxicity in Solid Tumors
Updated data from a first-in-human trial were presented at the SITC 2022 meeting.
KRAS-Directed TCR Therapy Shows Promising Preclinical Efficacy and Safety
AFNT-111 showed anti-tumor activity in NSG mouse models of breast cancer, pancreatic cancer, and colon cancer.
Omid Hamid, MD, on Improving Duration of Response in Refractory Melanoma With Lifileucel
The chief of research and immunotherapy at Cedars-Sinai The Angeles Clinic and Research Institute discussed updated data from the phase 2 C-144-01 study of the lifileucel TIL therapy.
HLA LOH-Targeting Tmod Cell Therapies Demonstrate Selective Killing of Tumor Cells in Mice
A2B530 and A2B694 target CEA and MSLN cells that have HLA loss of heterozygosity.
Personalized TCR Therapy Safe, Feasible in First-in-Human Trial
Among the 16 patients treated in the trial, 5 showed stable disease after treatment.
CRISPR-CAR T Therapy Yields First Allogeneic Complete Response in R/R Solid Tumors
Data from the COBALT-RCC study in renal cell carcinoma were presented at SITC 2022.
TIL Therapy Demonstrates Durable Efficacy and Manageable Safety in Heavily Pretreated Advanced Melanoma
The data included an IRC-assessed ORR of 31.4%.
Patient With Appendix Carcinoma Shows Stable Disease After Treatment With PBMC Therapy
The patient’s ECOG performance status remained at 0 from screening through the rest of trial participation.
Susan Foy, PhD, on Evaluating Personalized, Neoantigen-Specific T Cell Therapy in Solid Tumors
The CRIPSR-edited neoantigen-specific T cell therapy demonstrated safety and feasibility in the first-in-human PACT-0101 study presented at SITC 2022.
Gene Expression Profiles Characterize CAR T-Cells in Solid and Hematological Tumors
Further analysis will be performed to elucidate which characteristics correlate with optimal cell therapy behavior.
Treating Solid Tumors With Personalized Immunotherapy: Julian Molina, MD, PhD
The hematologist/oncologist from Mayo Clinic discussed targeting HLA loss in solid tumors.
Challenges of Cell Therapy in Solid Tumors: Julian Molina, MD, PhD
The hematologist/oncologist from Mayo Clinic discussed advantages of Tmod cell therapy in solid tumors.
Improving Specificity of T-Cell Therapies in Solid Tumors: Julian Molina, MD, PhD
The hematologist/oncologist from Mayo Clinic discussed advantages of Tmod technology in solid tumors.
Improving Outcomes in Solid Tumors With Personalized Cell Therapies
Cedrik Britten, MD, chief medical officer, Immatics, discussed the advantages of IMA203 over other cell therapies.
Improving Cancer Survival With Immunotherapy: Julian Molina, MD, PhD
The hematologist/oncologist from Mayo Clinic discussed the growing presence of CAR T-cell therapies in lung cancer and melanoma.
Initial Results of CT-0508 in HER2+ Solid Tumors: Kim A. Reiss Binder, MD
The oncologist from Abramson Cancer Center, Penn Medicine discussed the initial results of the phase 1 trial of CT-0508 in HER2-overexpressing solid tumors.
Using HLA LOH as a Biomarker in Targeting Cancers: Julian Molina, MD, PhD
The hematologist/oncologist from Mayo Clinic discussed the role of HLA loss in common cancers and its use as a biomarker.
Improving Personalized Cell Therapies for Solid Tumors
Cedrik Britten, MD, chief medical officer, Immatics discussed data on IMA203 presented at SITC 2021.
2 Clarke Drive Cranbury, NJ 08512